1. Home
  2. CYBN vs BIOA Comparison

CYBN vs BIOA Comparison

Compare CYBN & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cybin Inc.

CYBN

Cybin Inc.

HOLD

Current Price

$6.62

Market Cap

298.9M

Sector

Health Care

ML Signal

HOLD

Logo BioAge Labs Inc.

BIOA

BioAge Labs Inc.

HOLD

Current Price

$12.97

Market Cap

175.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYBN
BIOA
Founded
2019
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
298.9M
175.7M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
CYBN
BIOA
Price
$6.62
$12.97
Analyst Decision
Strong Buy
Buy
Analyst Count
4
4
Target Price
$74.50
$11.33
AVG Volume (30 Days)
610.5K
403.7K
Earning Date
11-13-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,917,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.81
$2.88
52 Week High
$10.73
$13.10

Technical Indicators

Market Signals
Indicator
CYBN
BIOA
Relative Strength Index (RSI) 60.06 83.65
Support Level $5.70 $12.00
Resistance Level $6.20 $13.10
Average True Range (ATR) 0.35 0.72
MACD 0.08 0.32
Stochastic Oscillator 85.82 97.20

Price Performance

Historical Comparison
CYBN
BIOA

About CYBN Cybin Inc.

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

About BIOA BioAge Labs Inc.

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.

Share on Social Networks: